Disease severity of the first COVID-19 wave in Germany using reporting data from the national notification system by Schilling, Julia et al.
1
FEDERAL HEALTH REPORTING  
JOINT SERVICE BY RKI AND DESTATIS 
Journal of Health Monitoring
Disease severity of the first COVID-19 wave 
in Germany using reporting data from the 
national notification system 
FEBRUARY 2021
SPECIAL ISSUE 11
Disease severity of the first COVID-19 wave in Germany using reporting data from the national notification systemJournal of Health Monitoring
2
FOCUS
Transparency in Healthcare (IQTIG), Berlin 




Disease severity of the first COVID-19 wave in Germany using 
reporting data from the national notification system
Abstract
As of December 31, 2019, initial reports circulated internationally of an unusual cluster of pneumonia of unknown cause 
in China. By the end of January 2020, the virus affected Germany with the first case confirmed on January 27, 2020. 
Intensive contact tracing and infection control measures contained the first two clusters in the country. However, the 
dynamic of the first wave gained momentum as of March, and by mid-June 2020 over 190,000 laboratory-confirmed 
cases had been reported to the Robert Koch Institute. This article examines these cases as part of a retrospective 
descriptive analysis focused on disease severity. Most cases (80%) were mild and two thirds of the cases were younger 
than 60 years (median age: 50 years). Severe cases were primarily reported among men aged 60 or over who had at least 
one risk factor (particularly cardiovascular disease, diabetes, neurological disorders and/or lung diseases). Cases between 
the ages of 40 and 59 years had the longest interval between symptom onset and hospitalisation (median: six days) and 
– if admitted to an intensive care unit (ICU) – also the longest ICU stay (median: eleven days). This analysis provides
valuable information about disease severity of COVID-19 and particularly affected groups.
  COVID-19 · PANDEMIC · FIRST WAVE · GERMANY · SEVERITY OF DISEASE · NATIONAL NOTIFICATION SYSTEM
1. Introduction
As of December 31, 2019, initial reports circulated interna-
tionally of an unusual cluster of pneumonia of unknown 
cause in China [1]. Initial investigations suggested an epi-
demiological link to Huanan Seafood Market in Wuhan 
(Hubei Province, China) and a zoonotic (animal) origin. 
A few days later, on January 9, 2020, the World Health 
Organization (WHO) officially confirmed that the previous-
ly unknown virus was a corona virus. Initially titled 2019-
nCoV, the virus has now been categorised as Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and 
the disease as Coronavirus Disease-2019 (COVID-19) [2]. 
Due to the close link to Wuhan, human-to-human trans-
missions was assumed to be limited at that time. This 
assessment changed soon as the number of cases increased 
continuously in China and the epidemic began spreading 
to other countries.
By the end of January 2020, the virus affected Germany 
with the first case confirmed on January 27, 2020 [3]. This 
case was a 33-year-old man employed by a company in 
Bavaria. In the course of the investigation, a colleague from 
the Chinese branch of the company, who had travelled from 
China to facilitate workshops and meetings, was identified 
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Protection against Infection Act (Infektionsschutzgesetz, 
IfSG) and subsequently reported to the federal state author-
ity and further to the national database of notifications at 
the Robert Koch Institute (RKI) [8]. All cases reported to 
the Robert Koch Institute up to October 26, 2020 were 
included in line with the case definition of the RKI for lab-
oratory confirmed infections of SARS-CoV-2. Therefore only 
laboratory-confirmed cases (pathogen isolation, Nucleic 
acid detection) with SARS-CoV-2 infection, irrespective of 
clinical symptoms are reported [8].
A total of 437,866 COVID-19 cases had been reported 
to the RKI by 26 October 2020. Of these, 190,816 cases 
originated from January 2020 until mid-June 2020, or 
reporting week 25. This study only includes cases that 
provide data on age, hospital status and death (n=166,662 
by reporting week 25). In addition, hospital admission 
and discharge dates were also required to calculate peri-
ods in context of hospitalisation. This information was 
only available in around half of all cases, with a contin-
uous decrease in the number of cases that provided this 
information as of reporting week 20. Assessing disease 
severity based on current case numbers may lead to an 
underestimation of the proportions of severe and fatal 
cases. In order to assess disease severity regarding pro-
portions of serious disease outcomes and fatal cases, 
only numerators and denominators should be used for 
periods where relatively reliable information is available 
for both parameters. Previous analyses have shown that 
completeness of hospitalisation data decreases contin-
uously the closer the reporting date is to the date of the 
analysis. As we assume that missing data would not be 
provided in a timely manner and further corrections are 
as the source of the infection [4, 5]. Finally, contract tracing 
and investigations at the local, regional and national level 
have been crucial measures to contain this first outbreak 
in Germany. A second cluster consisted of two cases that 
were among a group of individuals, who were repatriated 
from China. They were tested positive after their arrival and 
were subsequently hospitalised for isolation, whereas the 
other passengers, repeatedly tested negative, remained in 
quarantine for two weeks [3]. These first two outbreaks 
provided valuable information about the transmission of 
the novel virus in Germany. The dynamic of the first corona 
virus wave in Germany gained momentum in February, 
worsened at the beginning of March and was triggered by 
outbreaks related to carnival events and to individuals 
returning from ski resorts (especially from Italy and 
Austria) [6]. Extensive infection and control measures were 
implemented and contained this first wave until mid-June. 
The situation in Germany has been continually assessed 
using the Pandemic Influenza Severity Assessment by 
WHO (PISA) [7], considering transmission, disease sever-
ity and impact on the health system.
Based on reported data from the national notification 
system, the first COVID-19 wave in Germany was analysed 
focussing on disease severity as one part of the risk assess-
ment and in order to prepare for the upcoming autumn/
winter season.
2. Methods
The following descriptive, retrospective analysis is based 
on laboratory-confirmed cases with a SARS-CoV-2 infection 
notified to the local health authority in line with the 
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for binary responses (‘yes’ or ‘no’), with the default set 
to ‘no’. However, an additional parameter – the general 
availability of clinical data (‘yes’, ‘no’) – was previously 
considered. This enabled a clearer differentiation to be 
made between responses and was used to evaluate mild 
and moderate cases and symptoms.
Fatal cases were defined as laboratory confirmed cases 
with a SARS-CoV-2 infection who were reported to have 
died due to COVID-19 (“died of”) as well as people who 
had underlying conditions (in addition to COVID-19). In 
the latter case, it is impossible to conclusively identify the 
cause of death, but COVID-19 is assumed to have con-
tributed to the death (“died with”).
The findings set out here on risk factors are based on 
the risk factors that can be entered into the notification 
software; these include diseases of the cardiovascular 
system, diabetes, neurological disorders, lung diseases, 
kidney diseases, cancer, immunological disorders and 
liver diseases.
3. Results
Once the first cases connected to a cluster in Bavaria and 
a group of people who had been repatriated to Germany 
became known at the end of January/beginning of Febru-
ary, the COVID-19 outbreak gained momentum. This was 
particularly the case at the beginning of March 2020, and, 
as of reporting week 10, the outbreak developed into 
Germany’s first wave of COVID-19 (Figure 1).
not to be expected, the analysis of the first wave only 
includes cases that were reported by reporting week 20 
(n=152,984).
Furthermore, intervals were calculated using cases 
with only one hospital stay. Intervals relating to symptom 
onset considered only cases with symptom onset before 
hospital/intensive care unit (ICU) admission and before 
cut-off date (October 26, 2020). Calculations of the length 
of hospitalisation/ICU-stay only considered cases with 
information on admission and discharge dates before 
26 October 2020. Date of death was used in lieu of a 
discharge date if this was not available.
Incidences were calculated using the standard Ger-
man population as of 31 December 2019. Analyses were 
carried out with StataSE 15, Microsoft Excel 2010 and R 
(version 3.6.1).
In line with the premise of providing ‘two meaningful 
digits’, figures that are lower than ten are given to one 
decimal point, whereas whole numbers are provided in 
other cases.
A distinction is made between mild, moderate, severe 
and critical cases (Info box), but these distinctions are 
not mutually exclusive. These categories are based on the 
initial description of disease severity drawn up by the 
WHO [9] during the first joint mission that took place in 
China and a preliminary assessment of disease severity 
using the reported data from the national notification 
system [10].
Symptoms (e.g. cough, runny nose) and severity 
parameters (e.g. acute respiratory distress syndrome 
(ARDS) and ventilation) can be entered into the notifica-




Definition based on the 
notification software
Mild Clinical data available, no 
pneumonia, no hospitalisation, 
not deceased
Moderate Clinical data available, 
pneumonia, no hospitalisation, 
not deceased 
Severe Hospitalised (regardless of 
availability of clinical data, 
intensive care and death)
Critical Hospitalised, intensive care 
(regardless of availability of 
clinical data and death)
Fatalities (regardless of 
availability of clinical data and 
hospitalisation)
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60- to 79-year-olds (19%, n=29,492). Although only 12%
of cases (n=17,822) occurred among the oldest group (80
years or above), this group was most affected by the dis-
ease with an age-specific cumulative incidence of 314 cas-
es per 100,000 inhabitants, followed by 40- to 59-year-olds
(226 per 100,000) and 20- to 39-year-olds (209 per
100,000). Infants, children and adolescents were general-
ly less affected with 37 cases per 100,000 among children
aged 0 to 4 (1%, n=1,462), and 70 per 100,000 among
5- to 19-year-olds (5.2%, n=8,015). The percentage of cases
among older people (aged 60 or older) increased from 16%
3.1 Demographic distribution and symptoms
Around 52% of the 152,984 cases that had been reported 
by reporting week 20 and which provided information about 
age, hospitalisation and death involved women. Whereas 
at the beginning of the wave, slightly more men had been 
affected than women, by reporting week 14, this ratio had 
reversed and the proportion of cases rose among women. 
The rate peaked in reporting week 15 at 57%. The majority 
of all cases (35%, n=53,392) were among 40- to 59-year-


























0-4 years 5-19 years 20-39 years 40-59 years 60-79 years ≥80 years Median age
No COVID-19 cases were submitted for reporting week eight and accordingly no median age was calculated.
Figure 1 
Number of reported COVID-19 cases in 
Germany by age group and median age over 
time, up to reporting week 20 (n=152,984) 
Source: COVID-19 cases reported to the RKI 
(data as of 26 October 2020, 00:00)
The majority of COVID-19 
cases reported during the 
first wave were among young 
or middle-aged adults.
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symptoms included runny nose (22%, n=30,179) and sore 
throat (19%, n=26,961). Pneumonia and dyspnoea (short-
ness of breath) occurred primarily among people aged 
60 or older, whereas runny noses were much more com-
mon among younger age groups (Table 1). It has been pos-
sible to report loss of smell and taste as symptoms since 
reporting week 17. Between reporting week 17 and report-
ing week 20, at least one of these symptoms was reported 
in 9.1% (2,126 of 23,403) of cases.
3.2 Disease severity level
As 80% of all cases with clinical data (n=110,789) were not 
reported to have resulted in hospitalisation, pneumonia, or 
death, they were assumed to have been mild (Table 2). The 
percentage of mild cases was highest among younger groups, 
in reporting week 10 to around 37% in reporting week 15. 
In contrast, the percentage of cases among 40- to 59-year-
olds, which was around 48% in reporting week 11, decreased, 
and by reporting week 20 had stabilised at around 30%; 
the same applies to cases among 20- to 39-year-olds, which 
account for 32% of cases. This same distribution of cases 
by age over time is also clear from the median age, which 
increased from 43 years in reporting week 10 to 53 years in 
reporting week 15, but had decreased again to 46 years by 
reporting week 20 (Figure 1). Overall, both the median and 
the mean value are 50 years.
Clinical data was available in 138,464 of the 152,984 
cases. Across all age groups, coughs (51%, n=70,099), fever 
(42%, n=58,447) and general symptoms such as weakness, 
and muscle and body aches (38%, n=52,025) were most 
frequently reported. Other frequently reported respiratory 
Symptom 0–4 years 5–19 years 20–39 years 40–59 years 60–79 years ≥80 years Total
N (clinical data available) 1,251 7,012 39,023 49,451 26,788 14,939 138,464
N (number of responses) 1,835 11,230 76,902 102,149 52,097 23,213 267,426
% % % % % % %
Coughs 40 42 52 57 50 33 51
Fever 48 34 39 45 45 40 42
General symptoms 18 30 38 40 39 33 38
Runny nose 23 25 29 24 16 6.9 22
Sore throat 8.5 21 25 22 14 5.1 19
Dyspnoea 2.2 3.2 7.1 8.3 13 16 9.3
Diarrhoea 6.5 4.7 6.2 7.9 9.0 6.6 7.3
Pneumonia 0.6 0.2 0.7 2.0 7.0 11 3.5
ARDS 0.1 0.1 0.2 0.6 2.1 2.5 1.0
Tachycardia 0.1 0.0 0.1 0.2 0.5 0.5 0.2
Tachypnoea 0.1 0.0 0.1 0.1 0.1 0.2 0.1
Table 1 
Age-specific percentage of reported symptoms 
in cases with clinical data 
(n=138,464, multiple responses possible)*
Source: COVID-19 cases reported to the RKI 
(data as of 26 October 2020, 00:00)
* It has only been possible to report loss of smell and taste since reporting week 17; these data are not shown here. 
ARDS = Acute Respiratory Distress Syndrome
Most cases were mild.
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sented without any reported risk factors. Overall, many cases 
that resulted in hospitalisation involved at least one reported 
risk factor (70%, n=10,017). The most frequently mentioned 
risk factors were cardiovascular diseases (67%), diabetes 
(29%) and neurological disorders (29%) (Table 4).
Critical cases (intensive care, fatalities)
A total of 24,827 cases that resulted in hospitalisation 
included data about whether the patient had been treated 
in ICU. Among these, 14% (n=3,418) received treatment in 
ICU (Table 2); the majority were men (70%, n=2,396). The 
largest percentage of cases treated in intensive care was 
during reporting week 13 (859 cases, 19%). Among all cas-
es treated in ICU that provided information on clinical data 
(n=3,290) – including, therefore, data about whether the 
patient had received ventilation – 23% were ventilated. In 
total, 1,619 (47%) out of 3,418 ICU cases deceased; and 
among these 523 deceased in ICU (84% out of 626 with 
information on the relevant dates). Information about 
reported risk factors for patients treated in ICU was avail-
able in 61% of cases (2,071 of 3,418). Among these, 20% 
had no reported risk factor (n=418), one-third (31%, n=643) 
had one risk factor and 49% (n=1,010) had at least two risk 
factors (Table 3). The majority of patients who were treat-
ed in ICU had reported risk factors, but age-specific differ-
ences became apparent. More than half of 20- to 39-year-
olds treated in ICU (53%, n=35) had no reported risk factor. 
The percentage of patients with no risk factor lowered with 
increasing age, to 11% (n=54) among those aged 80 or 
above. The data shows that patients treated in ICU mainly 
had cardiovascular diseases (70%), followed by diabetes 
(33%) and neurological disorders (30%, Table 4).
and fell to 62% among 60- to 79-year-olds and to 38% among 
patients aged 80 or older. In contrast, the percentage of 
severe or critical cases was highest among patients aged 
80 or older. Almost every second case among this group 
resulted in a hospitalisation, and one in three cases ended 
in death. At least one risk factor was specified in 26% 
(n=12,478) of mild cases (Table 3) and the percentage of cas-
es with underlying conditions increased in line with disease 
severity – representing 89% of those who died (n=4,223).
Severe cases
A total of 18% of cases (n=27,466) were hospitalised, with 
the highest age-specific proportion among patients aged 80 
or older (48%, Table 2). The highest percentage of hospi-
talised cases occurred in reporting week 16 (22%) and in 
patients aged under 60 in reporting week 10 (0 to 4 years: 
25%; 5 to 19 years: 13%; 20 to 39 years: 13%; 40 to 59 years: 
20%). The highest percentage of hospitalised cases among 
the 60-to-79 age group occurred in reporting week 18 (43%) 
and for cases aged 80 or older in reporting week 12 (65%). 
Among men, 21% of cases were hospitalised; whereas this 
applies to 15% of women (men account for 55% of all hos-
pitalised cases; ratio of men to women=1.2). A total of 23% 
(n=6,321) of hospitalised cases deceased. The highest num-
bers of fatal cases in hospital (26%) among severe cases 
were reported in reporting week 14 (n=1,568) and reporting 
week 15 (n=1,242).
Information about risk factors was available in 52% of all 
hospitalised cases (n=14,245). One-third (30%, n=4,228) 
had no reported risk factor, whereas 17% (n=2,380) had more 
than three reported risk factors (Table 3). Severe cases 
among younger groups (0 to 39 years) in particular also pre-
Severe cases were reported 
predominantly among men 
aged 60 or older who had at 
least one risk factor.
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Total number of cases with information 
on disease severity level (yes, no)
Number of cases by 
disease severity level
Percentage (%) of all cases in this 
age group by disease severity level
Mild (no pneumonia, no hospitalisation, not deceased)
Total 138,464 110,789 80
0–4 years 1,251 1,099 88
5–19 years 7,012 6,772 97
20–39 years 39,023 36,940 95
40–59 years 49,451 43,777 89
60–79 years 26,788 16,488 62
≥80 years 14,939 5,713 38
Moderate (pneumonia, no hospitalisation, not deceased)
Total 138,464 442 0.3
0–4 years 1,251 1 0.1
5–19 years 7,012 11 0.2
20–39 years 39,023 101 0.3
40–59 years 49,451 195 0.4
60–79 years 26,788 101 0.4
≥80 years 14,939 33 0.2
Severe (hospitalisation, irrespective of intensive care and death)
Total 152,984 27,466 18
0–4 years 1,462 165 11
5–19 years 8,015 256 3.2
20–39 years 42,801 2,154 5.0
40–59 years 53,392 5,725 11
60–79 years 29,492 10,628 36
≥80 years 17,822 8,538 48
Intensive care (hospitalisation, and treated in intensive care)
Total 24,827 3,418 14
0–4 years 142 7 4.9
5–19 years 199 4 2.0
20–39 years 1,769 99 5.6
40–59 years 5,037 695 14
60–79 years 9,746 1,833 19
≥80 years 7,934 780 10
Fatalities (irrespective of symptoms and hospitalisation)
Total 152,984 8,616 5.6
0–4 years 1,462 1 0.1
5–19 years 8,015 1 0.0
20–39 years 42,801 31 0.1
40–59 years 53,392 374 0.7
60–79 years 29,492 2,819 9.6
≥80 years 17,822 5,390 30
Table 2 
Age-specific distribution according to 
disease severity level (n=152,984 cases). 
Data on mild and moderate courses refer to 
cases with clinical information (n=138,464)
Source: COVID-19 cases reported to the RKI 
(data as of 26 October 2020, 00:00)
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Total number of cases with 
information on risk factors (yes, no) 
No risk factor (%) One risk factor (%) Two risk factors (%) Three or more 
risk factors (%)
Mild (no pneumonia, no hospitalisation, not deceased)
Total 47,767 35,289 (74) 8,282 (17) 3,092 (6.5) 1,104 (2.3)
0–4 years 460 429 (93) 22 (4.8) 6 (1.3) 3 (0.7)
5–19 years 2,865 2,673 (93) 172 (6.0) 17 (0.6) 3 (0.1)
20–39 years 15,780 14,097 (89) 1,426 (9.0) 228 (1.4) 29 (0.2)
40–59 years 18,781 13,817 (74) 3,636 (19) 1,069 (5.7) 259 (1.4)
60–79 years 7,390 3,675 (50) 2,210 (30) 1,116 (15) 389 (5.3)
≥80 years 2,491 598 (24) 816 (33) 656 (26) 421 (17)
Moderate (pneumonia, no hospitalisation, not deceased)
Total 174 104 (60) 41 (24) 25 (14) 4 (2.3)
0–4 years 1 1 (100) 0 (0) 0 (0) 0 (0)
5–19 years 6 6 (100) 0 (0) 0 (0) 0 (0)
20–39 years 40 32 (80) 7 (18) 0 (0) 1 (2.5)
40–59 years 81 49 (60) 23 (28) 8 (9.9) 1 (1.2)
60–79 years 34 12 (35) 10 (29) 11 (32) 1 (2.9)
≥80 years 12 4 (33) 1 (8.3) 6 (50) 1 (8.3)
Severe (hospitalisation, irrespective of intensive care and death)
Total 14,245 4,228 (30) 4,500 (32) 3,137 (22) 2,380 (17)
0–4 years 68 58 (85) 5 (7.4) 5 (7.4) 0 (0)
5–19 years 119 86 (72) 19 (16) 11 (9.2) 3 (2.5)
20–39 years 989 730 (74) 192 (19) 55 (5.6) 12 (1.2)
40–59 years 2,822 1,418 (50) 847 (30) 377 (13) 180 (6.4)
60–79 years 5,644 1,226 (22) 1,969 (35) 1,388 (25) 1,061 (19)
≥80 years 4,603 710 (15) 1,468 (32) 1,301 (28) 1,124 (24)
Intensive care (hospitalisation, and treated in intensive care)
Total 2,071 418 (20) 643 (31) 516 (25) 494 (24)
0–4 years 2 1 (50) 1 (50) 0 (0) 0 (0)
5–19 years 2 0 (0) 0 (0) 1 (50) 1 (50)
20–39 years 66 35 (53) 19 (29) 10 (15) 2 (3.0)
40–59 years 396 151 (38) 128 (32) 65 (16) 52 (13)
60–79 years 1,099 177 (16) 358 (33) 290 (26) 274 (25)
≥80 years 506 54 (11) 137 (27) 150 (30) 165 (33)
Fatalities (irrespective of symptoms and hospitalisation)
Total 4,735 512 (11) 1,428 (30) 1,436 (30) 1,359 (29)
0–4 years 0 0 (0) 0 (0) 0 (0) 0 (0)
5–19 years 1 0 (0) 1 (100) 0 (0) 0 (0)
20–39 years 17 5 (29) 7 (41) 5 (29) 0 (0)
40–59 years 224 47 (21) 81 (36) 47 (21) 49 (22)
60–79 years 1,575 174 (11) 498 (32) 440 (28) 463 (29)
≥80 years 2,918 286 (9.8) 841 (29) 944 (32) 847 (29)
Table 3 
Age-specific distribution of cases with data 
on risk factors (n=65,872)
Source: COVID-19 cases reported to the RKI 
(data as of 26 October 2020, 00:00)
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and, depending on the interval in question, that also pro-
vided data about symptom onset, hospital admission date 
and/or death. 
Interval between symptom onset and hospital admission
In total, 75% of cases were hospitalised within eight days 
of symptom onset; 50% were hospitalised after four days 
(Table 5). The interval between symptom onset and hospi-
tal admission was one day longer among cases treated in 
ICU (median: five days), and one day shorter (median: three 
days) among fatalities. The highest percentage of people 
admitted to hospital on the day of symptom onset (25%) 
was found among cases aged 0 to 4 and among those aged 
80 or above. In contrast, the longest interval between symp-
tom onset and hospital admission was identified among 
40- to 59-year-olds (median: six days).
Length of hospital stay
The cases considered in this study were hospitalised for a 
median of nine days (Table 5). In total, 75% were discharged 
after about two weeks at the latest (interquartile range: 
A total of 5.6% (n=8,616) of the cases considered 
resulted in death (Table 2). More fatalities occurred among 
men than women (56%, n=4,833). Moreover, most fatal 
cases were among cases aged 60 or older (95%) and, in 
particular, 79 or above (63%). Out of the 8,616 fatal cases, 
6,321 cases had been hospitalised (73%) and 1,619 had 
been treated in ICU (this amounts to 26% of fatalities that 
occurred in hospital). Among hospitalised fatal cases in 
ICU, and that provided clinical data, 341 had acute respira-
tory failure (ARDS) and 416 had been ventilated. Informa-
tion about risk factors was available for 55% (n=4,735) of 
the fatal cases: around one-third had either one, two or 
three risk factors, respectively, whereas 11% had no risk 
factors (Table 3). The most frequently reported risk factors 
were cardiovascular disease (74%), neurological disorders 
(37%) and diabetes (30%, Table 4).
3.3 Intervals relating to hospitalisation
Intervals relating to hospitalisation were calculated using 
cases that had only been hospitalised once (n=151,014, 99%) 
Risk factors Total Hospitalised Intensive care unit Fatalities
n % n % n % n %
Cases with at least one risk factor 24,085 10,017 1,653 4,223
Cardiovascular diseases 14,816 62 6,682 67 1,156 70 3,125 74
Neurological disorders 6,119 25 2,893 29 494 30 1,543 37
Diabetes 5,649 24 2,863 29 549 33 1,275 30
Lung diseases 5,309 22 2,171 22 418 25 914 22
Kidney disease 2,725 11 1,647 16 316 19 978 23
Immunological disorders 2,360 9,8 1,051 11 172 10 418 9.9
Cancer 2,425 10 1,297 13 218 13 620 15
Liver disease 683 2.8 352 3.5 75 4.5 160 3.8
Table 4 
Distribution of reported 
risk factors in severe cases 
(n=24,085, multiple responses possible)
Source: COVID-19 cases reported to the RKI 
(data as of 26 October 2020, 00:00)
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hospitalisation, regardless of whether they were ventilated 
or resulted in a fatality (Table 5). No difference was identi-
fied by age group or sex.
Length of ICU stay
Of the 3,418 cases that required intensive care, only 723 cas-
es (21%) could be considered (as the majority of cases did 
not provide dates). On average, cases spent a median of nine 
days in intensive care (Table 5). The majority (75%) received 
intensive care for no more than 18 days (interquartile range: 
4 to 17 days). The median length of hospitalisation was 
longest among 60- to 79-year-olds at eleven days, followed 
by ten days among cases aged 80 or older. In addition, the 
length of hospitalisation increased with disease severity 
(with the exception of fatalities).
Interval between hospital admission and ICU admission
On average, cases that were admitted to hospital were 
moved directly to ICU (median: zero days); 75% of cases 
required intensive care no later than three days after 
Table 5 
Intervals (in days) related to hospitalisation and 
death by age group, sex, intensive care status, 
ventilation status and death
Source: COVID-19 cases reported to the RKI 
(data as of 26 October 2020, 00:00)
* Empty cells: no differentiation was made by ICU status for intervals relating to the length of a stay in ICU, because they already include all cases that involved a
stay in ICU. For intervals calculated using the date of death, no differentiation was made for fatal cases because these cases are already included in the calculation.
Any discrepancies between individual categories and the total number of cases are due to missing information.
d = days, ICU = intensive care unit, IQR = interquartile range, N.A. = no data 






Length of ICU stay Hospital admission 
until death in hospital
Symptom onset 
until death
n Median d 
(IQA)
n Median d 
(IQA)
n Median d 
(IQA)
n Median d 
(IQA)
n Median d 
(IQA)
n Median d 
(IQA)
Total 14,043 4 (1–8) 11,504 9 (4–17) 723 0 (0–3) 723 9 (4–18) 4,532  9 (5–18) 5,888 11 (7–18)
Age groups
0–4 years 78 1 (0–3) 67 2 (1–4) 1 0 (0–0) 1 5 (5–5) 0 N.A. 0 N.A.
5–19 years 97 3 (1–7) 72 2 (1–5) 0 N.A. 0 N.A. 1 38 (38–38) 1 37 (37–37) 
20–39 years 1023 5 (2–9) 685 4 (2–9) 15 0 (0–1) 15 5 (2–13) 15 16 (10–22) 21 20 (11–29)
40–59 years 3,325 6 (3–9) 2,165 7 (4–12) 108 0 (0–2) 108 11 (6–21) 216 15 (7–26) 264 17 (9–28)
60–79 Jahre 5,463 4 (1–8) 4,302 11 (6–19) 393 0 (0–3) 393 10 (4–19) 1,686 12 (6–21) 1,931 14 (8–23)
≥80 years 4,057 2 (0–6) 4,213 10 (5–18) 206 0 (0–4) 206 6 (3–11) 2,614 8 (4–15) 3,671 10 (6–16)
Sex
Women 6,026 4 (1–8) 5,038 9 (4–16) 206 0 (0–3) 206 8 (3–15) 1,745 8 (4–16) 2,532 10 (6–16)
Men 8,011 4 (1–8) 6,416 9 (5–17) 517 0 (0–3) 517 9 (4–18) 2,786 10 (5–19) 3,355 12 (7–20)
Intensive care unit
Yes 2,093 5 (1–8) 1,762 14 (7–25) 1,200 11 (6–21) 1,174 16 (9–25)
No 11,950 4 (1–8) 9,742 8 (4–15) 3,332 9 (4–16) 3,014 11 (7–17)
Ventilation
Yes 696 4 (1–8) 609 16 (7–29) 161 0 (0–3) 161 12 (6–20) 437 12 (6–23) 456 16 (9–27)
No 13,347 4 (1–8) 10,895 9 (4–16) 562 0 (0–3) 562 8 (3–17) 4,095 9 (4–17) 5,432 11 (6–17)
Fatalities
Yes 3,337 3 (0–6) 4,709 9 (5–18) 500 0 (0–3) 500 8 (3–16)
No 10,706 5 (1–9) 6,795 9 (4–16) 223 0 (0–3) 223 11 (5–21)
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The majority of cases were identified among young and 
middle-aged adults
The first wave of COVID-19 in Germany was characterised 
by a high proportion of cases in adults between the ages 
of 20 and 59 (63%). At the beginning of the outbreak, the 
affected population was comparatively young, with a medi-
an age of 43 years. However, by reporting week 20, the pro-
portion of older cases increased, and the final median age 
of 50 years over the entire observation period corresponds 
to the first descriptions of the pandemic in China [11, 12]. 
With an incidence of 314 cases per 100,000 inhabitants, 
cases aged 80 or above were most affected. The large num-
ber of outbreaks in old people’s and nursing homes at the 
peak of the wave in spring 2020 may have played a role in 
this, and would also explain the high incidence in this age 
group [13]. Buda et al. outline that outbreaks in nursing 
homes rose continuously between reporting week 13 and 
reporting week 22, averaging around 19 cases per outbreak. 
Moreover, these outbreaks led more frequently to trans-
missions compared with outbreaks in other settings (e.g. 
households) [13].
The majority of cases were mild
In total, the first wave of COVID-19 in Germany was pri-
marily characterised by mild cases (80%). However, the 
proportion of mild cases decreases in the age group 60 
years and older and is 38% in the oldest group (80 or old-
er). These findings coincide with the first results from 
China [14–16], which described old age as the greatest risk 
factor associated with severe cases and those resulting 
in death [12, 16, 17]. In addition to a large number of cases 
among younger people with a comparatively high 
4 to 18 days); men required intensive care slightly longer than 
women. The longest length of stay in ICU (median: eleven 
days) was identified among 40- to 59-year-olds, followed by 
60- to 79-year-olds (median: ten days). If fatal cases are
excluded (n=223, median eleven days, interquartile range:
5 to 21 days), 40- to 59-year-olds still remained for the longest 
period in ICU with a median of 13 days (interquartile range:
8 to 20), followed by cases aged 80 or older (median twelve
days, interquartile range: 4 to 29).
Interval between hospital admission and death (in hospital)
A median of nine days elapsed between hospital admission 
and death in hospital (Table 5); 75% of these cases had 
died by their 18th day in hospital (interquartile range: 5 to 
18 days). On average, this interval was shorter among the 
very old (median: eight days) and longer among younger 
groups, men and by increasing severity.
Interval between symptom onset and death
A median of eleven days passed between symptom onset 
and death (Table 5); 75% of fatal cases died within 18 days 
of symptom onset (interquartile range: 7 to 18 days). On 
average, this period was one day shorter among cases over 
80 (median: ten) and increased with decreasing age. In 
severe cases that required intensive care, the interval 
increased to up to 16 days (median).
4. Discussion
The aim of this article was to describe disease severity of 
COVID-19 during the first wave in Germany based on avail-
able surveillance data from the national notification system. 
The 40-to-59 age group was 
hospitalised at a later stage 
than other age groups and, 
on average, spent the longest 
time in intensive care.
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pandemic, hospitalisation was recommended for all patients 
who tested positive (including, therefore, for mild cases) in 
order to ensure isolation and which would explain the high 
proportion of hospitalisations among younger groups at 
the beginning of the wave. As the pandemic progressed, 
almost half of patients aged 80 or older and a third of 60- 
to 79-year-olds were admitted to hospital. The descriptive 
analysis also identified sex-specific differences between 
severe and critical cases: men accounted for 55% of hospi-
talisations and 70% of all cases treated in ICU. Men also 
spent one day longer in ICU (median). This is in line with 
other clinical reports that have also demonstrated more 
severe cases among men; these can probably be attributed 
to sex-specific differences in the immune response [22]. 
However, the evidence is inconclusive and research is still 
ongoing. The most common risk factors identified were 
diseases of the cardiovascular system, and diabetes. Com-
pared with the first preliminary analysis of disease severity 
[10], the proportion of cases with neurological disorders 
increased among all cases with at least one risk factor. At 
25%, these cases were represented as frequently as cases 
with diabetes. This could be due to the higher percentage 
of people from old people’s and nursing homes, among 
whom neurological disorders such as dementia are more 
common [13, 23, 24]. Diseases of the cardiovascular system 
and diabetes have also been identified as frequent risk fac-
tors in severe cases by other studies in Germany [25–29]. 
Karagiannidis et al. describe this aspect in detail and lists 
kidney disease and obesity as other common risk factors 
[30]. However, obesity cannot be reported systematically by 
local health authorities in the notification software and kid-
ney diseases are mentioned less frequently in the data, but 
proportion of mild disease, the extensive testing strategy 
put in place in Germany for early, precise detection will also 
have played a role in the high proportion of mild cases. 
Over time, this strategy was expanded to include contact 
tracing in outbreaks and the screening of certain popula-
tion groups so that more mild and asymptomatic cases 
were covered by the national notification system [18–21]. In 
addition, increased screening measures put in place due 
to the high risk in old people’s and nursing homes could 
have led cases among older people to be identified earlier 
and, therefore, to be treated more promptly. The short inter-
val between symptom onset and hospital admission in the 
age group 80 years and older (median: two days) would 
support this assumption.
Severe cases were reported predominantly among men 
aged 60 or older who had at least one risk factor
In total, 18% of cases resulted in hospitalisation and among 
these 70% had at least one reported risk factor. A compar-
ison of the results of this study with those of the first pre-
liminary analysis of disease severity [10] shows that the pro-
portion of cases with reported risk factors among 
hospitalised cases has increased from 50% to 70%. How-
ever, during the course of the pandemic, reporting of SARS-
CoV-2 cases in the notification software became easier, and 
as such, this increase could be explained by improvements 
in risk factor reporting. However, risk factors are also dis-
tributed differently by age group. Children, adolescents and 
young adults aged from 20 to 39, in particular, only made 
up a small proportion of hospitalisations, but were frequent-
ly admitted to hospital despite having no reported risk 
factor. It is important to note that at the beginning of the 
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(median). At the same time, this age group also demon-
strates the longest median ICU stay of eleven days (medi-
an total ICU stay nine days). In contrast, the shorter medi-
an stay in ICU identified among older cases could be 
related to the higher proportion of fatalities in older age 
groups. As such, the length of ICU stay was also calculat-
ed after excluding fatal cases. Among cases aged 80 or old-
er, the duration increased from a median of six to twelve 
days. In contrast, the length of stay among 40- to 59-year-
olds increased significantly less (by a median of two days); 
however, at 13 days (median), this group still had the long-
est stay in ICU. Since both, the interval between symptom 
onset and hospitalisation, as well as the length of time 
spent in intensive care, were longest in this age group, it 
is possible that the risk of severe cases that this age group 
faces is underestimated and that these cases are only 
admitted to hospital at a later and, therefore, more severe 
stage. As a result, they may require longer periods of hos-
pitalisation and intensive care due to the advanced stage 
of the disease. However, the small number of cases treat-
ed in intensive care that could be considered mean that 
this analysis can only provide limited findings in this regard, 
see also the limitations set out below.
4.1 Limitations
This analysis primarily faces the limitations typically asso-
ciated with notification and surveillance data. In line with 
legal requirements, cases are usually only recorded by the 
notification system if they have been documented within 
the health care system by resident doctors, hospitals, lab-
oratories, test centres or additionally by community 
do seem to play a stronger role, especially among fatal cas-
es [31]. A possible explanation for the differences between 
the results presented here and Karagiannidis et al. could be 
the predominant involvement of university hospitals in the 
latter study [30]. University hospitals specialise in severe 
cases and treat them disproportionately often due to the 
therapeutic options that they can provide, such as ECMO 
(extracorporeal membrane oxygenation) and renal replace-
ment therapies, which are, in turn, beneficial to these cases 
due to the patents’ risk factors. This would also explain the 
somewhat lengthier median stay in hospital identified by 
Karagiannidis et al. [30] (ten days), compared with eight 
days in Docherty et al. [32] and nine days in the present 
study. In a first study in Germany, Dreher et al. [33] identi-
fied a median of seven days, but used a study population 
of just 50 cases and did not include any patients who 
received intensive care. The present analysis suggests a 
median length of stay in ICU of nine days, which clearly 
deviates from Tolksdorf et al. (five days) [34]. The present 
analysis included a larger percentage of fatal cases in the 
calculation of ICU stay (69%) compared with Tolksdorf et al. 
[34] (30%). This suggests an overestimation of critical cas-
es in the present analysis due to a higher data complete-
ness among critical cases (cases in ICU, fatal cases), even
if these cases tend to be underrepresented in the notifica-
tion system as a whole (see Chapter 4.1).
The 40-to-59 age group was hospitalised later and, on 
average, spent the longest time in intensive care
The length of time between symptom onset and hospital 
admission is relevant to clinical management. This period 
was longest among the 40-to-59 age group, at six days 
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further research. In addition, the high proportion of fatal 
cases among the cases treated in ICU suggests that infor-
mation on ICU stay are better reported for fatal cases 
(or cases with a long period of hospitalisation) in the 
notification system, but at the same time are also overes-
timated. 
Finally, once cases have been reported and recorded, 
it is difficult for local health authorities to follow up on 
them and to gain information about changes over time 
and report this updated information afterwards. This can 
mean that precise information about disease severity, in 
particular, is delayed or unavailable. However, if further 
information is available, it is usually available for severe 
and critical cases. 
4.2 Conclusion
During the first COVID-19 wave in Germany, the majority 
of cases were mild. The high proportion of severe cases 
among people aged 60 or older confirms initial findings 
about the correlation between disease severity and increas-
ing age. The data on 40- to 59-year-olds, and this particu-
larly applies to critical cases, could indicate that the risk of 
severe disease increases earlier than previously thought; 
this should be further investigated. Cardiovascular diseas-
es, diabetes and neurological disorders were reported as 
relevant risk factors. Due to the limitations of the surveil-
lance data used here, however, it is not possible to deter-
mine causal relations between risk factors and disease 
severity. Nevertheless, this analysis provides valuable 
information about disease severity of COVID-19 and par-
ticularly affected groups.
facilities (e.g. kindergarten, schools). Accordingly, if peo-
ple with mild or asymptomatic disease do not visit doctors 
or test centres, they will not be diagnosed and thus not 
be captured by the notification system. In addition, objec-
tively and subjectively severe cases are more likely to lead 
to a doctor’s visit and this increases the likelihood of a 
diagnosis among certain age groups and with increasing 
severity. As such, mild and asymptomatic cases tend to 
be underreported whereas severe cases are disproportion-
ately overreported. The proportion of mild cases is con-
sistent with international experience; however, these num-
bers are also dependent on the recommended and 
implemented testing strategy as well as testing capacities 
(all of which had to be established at the beginning of the 
first wave) and the surveillance system in place (including 
case definitions and the fact that the analysis only includes 
laboratory-confirmed cases). It can be assumed that the 
proportion of mild cases in the present analysis also 
reflects the comprehensive testing strategy conducted in 
Germany. In comparison with other studies in Germany, 
hospitalised cases are well represented in the notification 
system, but cases requiring intensive care and, thus, ven-
tilation are clearly underrepresented. Data from Tolksdorf 
et al. [34] and Karagiannidis et al. [30] suggest that around 
one-third of hospitalisations require intensive care; where-
as this study found this to be 12%. A similar picture emerges 
for cases with existing risk factors. Data completeness 
for risk factors of 52% among hospitalised cases, who 
actually seem to be well reported, suggests a general 
underreporting of risk factors. Furthermore, the German 
notification system can only provide a rough distribution 
of risk factors and therefore can only provide direction for 
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